---

Disclaimer: This information is provided for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. Always seek the advice of a qualified healthcare professional for any medical conditions or concerns. Clinical decisions must always be based on the specific circumstances of each patient, professional judgment, and current clinical guidelines.

---

Hypertensive Nephropathy

Overview

• Definition: Hypertensive nephropathy, also known as hypertensive nephrosclerosis, refers to chronic kidney disease (CKD) that develops as a result of long-standing, poorly controlled systemic arterial hypertension. It is characterized by progressive damage to the renal vasculature (arteriolosclerosis), glomeruli (glomerulosclerosis), and tubulointerstitial tissue, leading to a gradual decline in kidney function, often presenting with proteinuria and reduced glomerular filtration rate (GFR).
• Epidemiology:
  • Hypertension is the second leading cause of end-stage renal disease (ESRD) globally, accounting for approximately 25-30% of ESRD cases in many developed countries.
  • Prevalence of CKD attributable to hypertension is estimated to be high, with many individuals remaining undiagnosed in early stages.
  • Disproportionately affects individuals of African descent, older adults, and those with a family history of hypertension or CKD.
• Classification:
  • Benign Hypertensive Nephrosclerosis: The most common form, resulting from chronic, typically moderate hypertension, characterized by slow, progressive kidney function decline over years to decades. Histologically, it involves hyaline arteriolosclerosis and focal segmental glomerulosclerosis.
  • Malignant Hypertensive Nephrosclerosis: Associated with severe, accelerated hypertension (malignant hypertension or hypertensive emergency), characterized by fibrinoid necrosis of arterioles, onion-skinning of interlobular arteries, and acute kidney injury. This is a medical emergency requiring immediate blood pressure reduction. While related, the focus of this document is primarily on the chronic form (benign).

Pathophysiology

• Mechanism:
  1. Renal Vasculopathy: Chronic elevated systemic blood pressure leads to structural and functional changes in renal arterioles.
     • Hyaline Arteriolosclerosis: Deposition of hyaline material in the walls of afferent and efferent arterioles, leading to thickening, luminal narrowing, and reduced blood flow.
     • Hyperplastic Arteriolosclerosis ("Onion Skinning"): In severe hypertension, concentric proliferation of smooth muscle cells and extracellular matrix in arterial walls, further narrowing the lumen.
  2. Ischemic Glomerular Injury: Reduced blood flow to glomeruli due to arteriolosclerosis causes chronic ischemia.
     • Glomerulosclerosis: Ischemia leads to compensatory hyperfiltration in surviving nephrons, causing endothelial damage, mesangial expansion, and eventual scarring (focal segmental glomerulosclerosis).
     • Loss of Nephrons: Irreversible damage to glomeruli and tubules results in nephron loss.
  3. Tubulointerstitial Fibrosis: Ischemia and inflammatory processes triggered by glomerular injury lead to tubulointerstitial inflammation and fibrosis, further impairing kidney function.
  4. Renin-Angiotensin-Aldosterone System (RAAS) Activation: Kidney ischemia can activate RAAS, leading to further vasoconstriction, sodium retention, and maladaptive effects on renal structure, creating a vicious cycle.
• Risk Factors:
  • Uncontrolled or Long-standing Hypertension: The primary and most critical risk factor.
  • Severity and Duration of Hypertension: Higher blood pressure and longer duration of hypertension increase risk.
  • Age: Older age is associated with increased risk due to cumulative exposure and age-related vascular changes.
  • Race/Ethnicity: Individuals of African descent have a higher incidence and severity, likely due to genetic predispositions (e.g., APOL1 gene variants) and socioeconomic factors.
  • Family History: Genetic predisposition to hypertension or CKD.
  • Diabetes Mellitus: Co-existence of diabetes significantly accelerates kidney damage.
  • Obesity: Contributes to hypertension and metabolic syndrome.
  • High Sodium Intake: Exacerbates hypertension.
  • Smoking: Accelerates vascular damage.
  • Hyperlipidemia: Contributes to atherosclerosis and vascular stiffness.
  • Male Sex: Some studies suggest a higher prevalence in men.
• Protective Factors:
  • Early and Aggressive Blood Pressure Control: Maintaining blood pressure within target ranges.
  • Adherence to Antihypertensive Medication: Consistent use of prescribed medications.
  • Lifestyle Modifications:
    • Dietary Approaches to Stop Hypertension (DASH) diet.
    • Sodium restriction (<2.3 g/day, ideally <1.5 g/day for hypertensives).
    • Regular physical activity (at least 150 min/week of moderate intensity).
    • Maintenance of a healthy body weight (BMI 18.5-24.9 kg/m²).
    • Limited alcohol intake (≤2 drinks/day for men, ≤1 drink/day for women).
  • Glycemic Control in Diabetics: Strict control of blood glucose.
  • Lipid Management: Control of dyslipidemia.

Clinical Presentation

Signs and Symptoms

Hypertensive nephropathy is often asymptomatic in its early stages. Symptoms typically manifest once significant kidney damage has occurred and GFR has fallen below a critical threshold. - Cardinal Features: - Often asymptomatic until advanced stages. - Persistent hypertension (often longstanding history). - Proteinuria (typically non-nephrotic, <1-2 g/day, but can progress). - Gradual, progressive decline in GFR. - Early Signs: - Microalbuminuria (albumin excretion rate 30-300 mg/24h or urine albumin-to-creatinine ratio [UACR] 30-300 mg/g). - Mildly elevated serum creatinine with no overt symptoms. - Nocturia (early sign of impaired kidney concentrating ability). - Advanced Signs: - Symptoms of uremia (fatigue, nausea, loss of appetite, pruritus, mental status changes). - Edema (peripheral, periorbital) due to fluid overload. - Dyspnea on exertion, orthopnea (due to fluid overload or associated cardiovascular disease). - Anemia (normocytic, normochromic). - Electrolyte imbalances (hyperkalemia, hyperphosphatemia). - Hypertensive retinopathy or left ventricular hypertrophy (LVH) (signs of end-organ damage from hypertension). - Atypical Presentations: - Rapid decline in GFR (if underlying malignant hypertension or an superimposed acute kidney injury). - Nephrotic-range proteinuria (>3.5 g/day) is rare in pure hypertensive nephropathy and should prompt investigation for other causes (e.g., focal segmental glomerulosclerosis as a secondary lesion, or co-existing primary glomerular disease).

Physical Examination

Findings are often subtle in early stages and become more prominent with advanced CKD and uncontrolled hypertension. - Inspection: - Peripheral edema (pitting edema, especially in lower extremities). - Pallor (suggestive of anemia). - Signs of hypertensive urgency/emergency (e.g., papilledema in malignant hypertension, altered mental status). - Palpation: - Peripheral pulses: May be diminished due to peripheral arterial disease. - Cardiac apex beat: Displaced laterally and inferiorly, sustained (suggestive of LVH). - Special Tests: - Blood Pressure Measurement: Essential for diagnosis and monitoring. Should be accurately measured in both arms, seated, after rest. Consider ambulatory BP monitoring for confirmation of sustained hypertension. - Fundoscopic Examination: To assess for hypertensive retinopathy (arteriolar narrowing, A-V nicking, hemorrhages, exudates, papilledema in severe cases). - Cardiovascular Examination: Auscultation for S3 gallop, murmurs (mitral regurgitation from LV dilatation), signs of fluid overload (jugular venous distension, pulmonary rales).

Diagnostic Approach

The diagnosis of hypertensive nephropathy is largely one of exclusion, based on a long history of hypertension, characteristic kidney changes, and the absence of other primary causes of CKd.

History Taking

• Key Questions:
  • Duration and Control of Hypertension: When was hypertension first diagnosed? What are the typical BP readings? Is it controlled with medication? Adherence to medications?
  • Antihypertensive Medications: Current and past medications, dosages, and side effects.
  • Family History: History of hypertension, kidney disease, or stroke in first-degree relatives.
  • Symptoms of CKD: Fatigue, nocturia, edema, pruritus, nausea, changes in urine output.
  • Comorbidities: History of diabetes mellitus, dyslipidemia, cardiovascular disease, peripheral artery disease.
  • Other Nephrotoxic Exposures: NSAID use, herbal supplements, contrast dye exposure.
  • History of Acute Kidney Injury (AKI): Any prior episodes?
  • Ethnic Background: African descent, as discussed under risk factors.
  • Dietary Habits: Sodium intake, processed foods.
• Red Flags:
  • Rapid decline in GFR: Suggests a more aggressive form of kidney disease, possibly malignant hypertension, or another primary renal disease (e.g., vasculitis, rapidly progressive glomerulonephritis).
  • Nephrotic-range proteinuria: Uncommon for pure hypertensive nephropathy; indicates need for further investigation including potential kidney biopsy.
  • Onset of kidney disease preceding hypertension: Suggests that hypertension may be secondary to kidney disease, rather than the cause.
  • Absence of retinopathy or LVH: While not absolute, their absence in someone with advanced CKD attributed to hypertension should raise suspicion for other causes.
  • Asymmetry in kidney size or presence of renal artery bruits: Suggestive of renal artery stenosis.

Laboratory Tests

• First-Line:
  • Serum Creatinine and eGFR: To assess kidney function. An eGFR <60 mL/min/1.73m² for >3 months indicates CKD.
  • Urinalysis with Microscopy: To check for proteinuria, hematuria, cellular casts. In hypertensive nephropathy, typically bland urine sediment with mild proteinuria. Hematuria or cellular casts suggest other glomerular diseases.
  • Urine Albumin-to-Creatinine Ratio (UACR): A preferred method for quantifying proteinuria; spot urine sample is sufficient. Microalbuminuria (30-300 mg/g) or macroalbuminuria (>300 mg/g) are common findings.
  • Electrolytes (Na, K, Cl, HCO3): To check for imbalances common in CKD (e.g., hyperkalemia, metabolic acidosis).
  • Blood Urea Nitrogen (BUN): Correlates with GFR but can be affected by other factors (e.g., dehydration).
• Confirmatory (and to rule out other causes):
  • Complete Blood Count (CBC): To assess for anemia of CKD.
  • Fasting Glucose/HbA1c: To screen for or monitor diabetes.
  • Lipid Panel: To assess for dyslipidemia.
  • Urine Protein Electrophoresis (UPEP) / Serum Protein Electrophoresis (SPEP) with Immunofixation: If nephrotic range proteinuria or suspicion of monoclonal gammopathy.
  • Autoimmune Markers (ANA, ANCA, anti-GBM): If there is suspicion of autoimmune kidney disease (e.g., rapidly progressive GFR decline, significant hematuria, cellular casts).
  • Complement Levels (C3, C4): To rule out complement-mediated glomerulonephritis.
  • Renal Duplex Ultrasound: To evaluate kidney size, rule out obstruction, and assess for renal artery stenosis (though MRA or CTA are more sensitive for RAS). In hypertensive nephropathy, kidneys are typically symmetrically small and scarred (increased echogenicity) in advanced stages.
  • Kidney Biopsy: Not routinely performed for classic hypertensive nephropathy. Indicated if:
    • Rapid or unexplained decline in GFR.
    • Nephrotic-range proteinuria (>3.5 g/day).
    • Active urine sediment (hematuria, cellular casts).
    • Unexplained kidney asymmetry.
    • Symptoms suggestive of systemic inflammatory disease.
    • To differentiate from other primary or secondary glomerular diseases.
• Monitoring:
  • eGFR and UACR: Regularly, typically every 3-12 months depending on CKD stage.
  • Blood Pressure: At every clinical visit.
  • Electrolytes: Regularly, especially if on diuretics or RAAS inhibitors.

Management

Acute Management (for Hypertensive Emergencies with Renal Involvement)

This refers to acute, severe BP elevations (e.g., systolic >180 mmHg or diastolic >120 mmHg) with acute organ damage, including the kidneys. - Immediate: - Rapid, but controlled, reduction of blood pressure. The goal is to reduce Mean Arterial Pressure (MAP) by no more than 20-25% in the first hour. Overly aggressive BP reduction can worsen renal ischemia. - Intravenous antihypertensives are typically required. - Stabilization: - Admit to ICU for close monitoring of BP, urine output, and renal function. - Identify and treat any precipitating factors (e.g., medication non-adherence, volume overload). - Emergency Pharmacological Options: - Nicardipine: Initial dose 5 mg/h IV, titrate by 2.5 mg/h every 5-15 min to max 15 mg/h. - Clevidipine: Initial dose 1-2 mg/h IV, double every 90 sec up to 21 mg/h. - Labetalol: Initial dose 20 mg IV push, then 20-80 mg every 10 min, or continuous infusion 0.5-2 mg/min. - Fenoldopam: 0.1-0.3 mcg/kg/min IV, vasodilator with beneficial renal effects. - Sodium Nitroprusside: 0.25-10 mcg/kg/min IV, potent vasodilator, but carries risk of cyanide toxicity, especially with prolonged use or renal impairment.

Chronic Management

The cornerstone of chronic management is strict blood pressure control, proteinuria reduction, and slowing the progression of kidney disease.

• Pharmacological:
  • First-Line (especially with proteinuria):
    • Renin-Angiotensin System (RAS) Inhibitors:
      • ACE Inhibitors (ACEi): e.g., Lisinopril 10-40 mg/day, Enalapril 5-20 mg BID, Ramipril 2.5-20 mg/day.
      • Angiotensin Receptor Blockers (ARBs): e.g., Losartan 50-100 mg/day, Valsartan 80-320 mg/day, Irbesartan 150-300 mg/day.
      • Mechanism: Reduce intraglomerular pressure, decrease proteinuria, and provide renoprotective effects independent of BP lowering.
      • Monitoring: Serum creatinine and potassium should be checked 1-2 weeks after initiation or dose escalation. A mild rise in creatinine (up to 30% from baseline) is generally acceptable, but significant rises require evaluation.
      • Contraindications: Pregnancy, bilateral renal artery stenosis (relative), angioedema (for ACEi).
  • Second-Line / Add-on Agents:
    • Diuretics:
      • Thiazide Diuretics: e.g., Hydrochlorothiazide 12.5-50 mg/day, Chlorthalidone 12.5-25 mg/day. First-line for hypertension if no significant CKD (eGFR >30 mL/min).
      • Loop Diuretics: e.g., Furosemide 20-80 mg BID, Torsemide 10-20 mg/day. Preferred for fluid overload and when eGFR <30 mL/min, as thiazides lose efficacy.
    • Calcium Channel Blockers (CCBs):
      • Dihydropyridines: e.g., Amlodipine 2.5-10 mg/day, Nifedipine XL 30-90 mg/day. Potent vasodilators, useful for BP lowering.
      • Non-dihydropyridines: e.g., Verapamil 120-480 mg/day, Diltiazem 120-360 mg/day. Can also reduce proteinuria and heart rate, but should be used cautiously with beta-blockers due to risk of bradycardia/AV block.
    • Beta-blockers: e.g., Metoprolol XL 50-200 mg/day, Carvedilol 6.25-25 mg BID. Useful for rate control, post-MI, or heart failure. Generally not first-line for hypertension unless specific indications.
    • Mineralocorticoid Receptor Antagonists (MRAs): e.g., Spironolactone 12.5-50 mg/day, Eplerenone 25-50 mg/day. Can be added for resistant hypertension or proteinuria despite maximal RAS inhibitor therapy, but careful monitoring of potassium and GFR is essential due to hyperkalemia risk, especially in advanced CKD.
    • SGLT2 Inhibitors: e.g., Dapagliflozin 10 mg/day, Empagliflozin 10 mg/day. Emerging evidence shows significant cardiorenal protection in CKD patients, with or without diabetes, including reducing the risk of CKD progression and cardiovascular events. Increasingly recommended as an add-on therapy, particularly in patients with diabetes and CKD, or non-diabetic CKD with proteinuria.
• Non-pharmacological:
  • Dietary Approaches to Stop Hypertension (DASH) Diet: Emphasizes fruits, vegetables, whole grains, low-fat dairy, and reduced saturated/total fat, cholesterol.
  • Sodium Restriction: Limit sodium intake to <2.3 g/day (ideally <1.5 g/day for those with hypertension/CKD).
  • Regular Physical Activity: At least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity aerobic activity per week.
  • Weight Management: Achieve and maintain a healthy body weight (BMI 18.5-24.9 kg/m²).
  • Alcohol Moderation: Limit to ≤2 drinks/day for men and ≤1 drink/day for women.
  • Smoking Cessation: Crucial for overall cardiovascular and renal health.
• Monitoring:
  • Blood Pressure: At every clinic visit; home BP monitoring is highly encouraged.
  • Renal Function (eGFR, serum creatinine): Every 3-12 months, depending on CKD stage and stability. More frequently after medication adjustments.
  • Proteinuria (UACR): Every 3-12 months.
  • Electrolytes (Potassium): Crucial, especially with RAS inhibitors and MRAs.
  • Lipid Panel and Glycemic Control (HbA1c): Periodically, if indicated.

Treatment Algorithms

• First-Line:
  1. Lifestyle Modifications: Initiate immediately and reinforce continuously.
  2. Blood Pressure Goal:
     • General Hypertensive Population (without CKD/diabetes): <130/80 mmHg (ACC/AHA 2017).
     • CKD Patients (including hypertensive nephropathy): Current guidelines (KDIGO 2021) recommend a SBP target of <120 mmHg using a standardized office BP measurement for most CKD patients, particularly if UACR is >30 mg/g. However, this is a strong recommendation based on low-certainty evidence. Many clinicians still target <130/80 mmHg, individualizing based on comorbidity and tolerability.
  3. Pharmacotherapy:
     • Primary agents: ACE Inhibitor or ARB, especially if proteinuria is present. Begin with a single agent and titrate to maximum tolerated dose.
• Second-Line:
  1. Dual Therapy: If BP goal not met, add a second agent. Typically, a CCB (dihydropyridine) or a thiazide diuretic (if eGFR >30 mL/min/1.73m²).
  2. SGLT2 Inhibitor: Consider adding an SGLT2 inhibitor in patients with CKD and proteinuria, regardless of diabetic status, for cardiorenal protection, provided eGFR is above the initiation threshold (e.g., >20-25 mL/min/1.73m² depending on the specific SGLT2i and current guidelines).
• Refractory Cases:
  1. Triple Therapy: If BP remains elevated, combine ACEi/ARB + CCB + Diuretic.
  2. MRA: Consider adding an MRA if resistant hypertension despite triple therapy, with careful monitoring for hyperkalemia and AKI.
  3. Alpha-blockers (e.g., Doxazosin, Terazosin): Can be used as fourth-line agents.
  4. Central Alpha-2 Agonists (e.g., Clonidine, Methyldopa): For highly refractory cases, though may have more side effects.
  5. Direct Vasodilators (e.g., Hydralazine, Minoxidil): Potent, but often require concurrent diuretics and beta-blockers to counteract reflex tachycardia and fluid retention. Minoxidil is highly effective but causes hirsutism and significant fluid retention.
  6. Referral to Hypertension Specialist or Nephrologist: For complex or highly refractory cases.
  7. Addressing Secondary Hypertension: Re-evaluate for secondary causes of hypertension if resistance is unexpected.
  8. Dialysis/Kidney Transplant: For patients progressing to ESRD.

Complications

• Common:
  • Progressive CKD: Leading to eventual ESRD.
  • Proteinuria: May worsen over time.
  • Electrolyte Imbalances: Hyperkalemia, hyperphosphatemia.
  • Anemia of CKD.
  • Metabolic Acidosis.
  • Mineral and Bone Disorder (CKD-MBD).
  • Volume Overload: Leading to edema, heart failure.
• Serious:
  • End-Stage Renal Disease (ESRD): Requiring dialysis or kidney transplantation.
  • Cardiovascular Events: Increased risk of myocardial infarction, stroke, heart failure, sudden cardiac death. This is the leading cause of death in CKD patients.
  • Hypertensive Emergencies: Malignant hypertension, hypertensive encephalopathy.
  • Left Ventricular Hypertrophy (LVH) and Diastolic Dysfunction.
  • Peripheral Artery Disease.
• Long-term:
  • Increased Morbidity and Mortality: Primarily from cardiovascular disease.
  • Reduced Quality of Life: Due to CKD symptoms and complications.
  • Need for Renal Replacement Therapy: Dialysis or transplantation.

Prognosis

• Factors:
  • Level of Blood Pressure Control: The most important modifiable factor. Better control leads to slower progression.
  • Initial GFR and Rate of Decline: Baseline kidney function and rate of deterioration.
  • Degree of Proteinuria: Higher levels of proteinuria correlate with faster progression to ESRD. Reduction in proteinuria is a key therapeutic goal.
  • Presence of Diabetes Mellitus: Co-existing diabetes significantly worsens prognosis.
  • Race/Ethnicity: African American patients tend to have a more aggressive course.
  • Genetics: APOL1 risk variants increase risk and accelerate progression in African Americans.
  • Adherence to Treatment: Consistent medication use and lifestyle modifications.
  • Presence of Comorbidities: Cardiovascular disease, obesity, dyslipidemia.
• Survival:
  • Survival for patients with hypertensive nephropathy is primarily determined by their cardiovascular risk.
  • Progression to ESRD typically occurs over decades in benign hypertensive nephropathy if BP is poorly controlled.
  • Once ESRD is reached, the 5-year survival rate on dialysis is significantly lower than that of the general population, although kidney transplantation offers better long-term outcomes.
• Quality of Life:
  • Gradually declines with worsening CKD symptoms and complications.
  • Requires significant lifestyle adjustments and medical management.

Prevention

• Primary: Preventing the initial occurrence of hypertension and kidney damage.
  • Lifestyle Modifications: Promoting a healthy diet (DASH), regular exercise, maintaining healthy weight, limiting sodium intake, avoiding smoking, and moderating alcohol.
  • Regular Health Check-ups: Early detection and management of hypertension.
• Secondary: Early detection and intervention to slow progression in individuals with hypertension.
  • Aggressive Blood Pressure Control: Consistent adherence to target BP goals.
  • Regular Screening for CKD: Periodic measurements of eGFR and UACR in all hypertensive patients.
  • Early use of RAAS Inhibitors: Especially in hypertensive patients with microalbuminuria.
  • Diabetes Management: Strict glycemic control in diabetic patients to prevent or delay microvascular complications including nephropathy.
• Tertiary: Preventing complications and improving outcomes in individuals with established hypertensive nephropathy.
  • Optimizing BP and Proteinuria Control: Continued aggressive management with multiple agents if necessary.
  • Managing Complications of CKD: Anemia, bone disease, electrolyte imbalances.
  • Cardiovascular Risk Reduction: Lipid management (statins), antiplatelet therapy where indicated.
  • Referral to Nephrology: Timely referral for advanced CKD (eGFR <30 mL/min/1.73m²).
  • ESRD Planning: Education and preparation for renal replacement therapy (dialysis or transplantation) if progression is anticipated.

Special Populations

• Pediatric:
  • Hypertensive nephropathy is less common but can occur in children with severe, prolonged hypertension (often secondary hypertension).
  • Diagnosis and management principles are similar, with emphasis on identifying and treating underlying causes of hypertension.
  • BP targets for children are age, sex, and height-specific (based on percentiles).
  • Long-term follow-up crucial due to long expected lifespan.
• Geriatric:
  • Older adults are more susceptible due to age-related changes in vascular stiffness and cumulative duration of hypertension.
  • Often have multiple comorbidities and polypharmacy, increasing risk of drug interactions and side effects.
  • BP targets may need to be individualized to avoid orthostatic hypotension or hypoperfusion, though guidelines still lean towards similar targets for fit older adults. Frail older adults may require less aggressive targets.
  • Start low, go slow with medications.
• Pregnancy:
  • Pre-existing hypertension can lead to chronic hypertensive nephropathy, which increases the risk of preeclampsia, gestational hypertension, and adverse fetal outcomes.
  • Certain antihypertensives are contraindicated (ACEi, ARBs) due to teratogenicity. Labetalol, Nifedipine, and Methyldopa are commonly used.
  • Monitoring of renal function and proteinuria is crucial throughout pregnancy.
• Comorbidities:
  • Diabetes Mellitus: Glycemic control is paramount. SGLT2 inhibitors and GLP-1 receptor agonists have renoprotective benefits. BP target may be more stringent.
  • Cardiovascular Disease (CVD): Management of hypertension is integrated with CVD risk reduction. Statins are often indicated. Avoidance of NSAIDs is important.
  • Heart Failure: ACEi/ARBs, beta-blockers, and MRAs are often used for both conditions, requiring careful monitoring of renal function and electrolytes. Diuretics are essential for volume control.
  • Obesity: Weight loss significantly improves BP control and reduces renal burden.

Clinical Pearls

• Diagnostic:
  • "The great mimicker": Always consider other causes of CKD, especially if GFR decline is rapid, proteinuria is significant/nephrotic, or urine sediment is active. Hypertensive nephropathy is a diagnosis of exclusion.
  • Symmetry: Bilaterally small and scarred kidneys on ultrasound support hypertensive nephropathy; asymmetry suggests other causes (e.g., renal artery stenosis, reflux nephropathy).
  • Time Course: A long history of hypertension (typically >10 years) preceding significant kidney dysfunction is characteristic.
  • Microalbuminuria is Key: It's often the earliest sign of hypertensive renal damage and a strong predictor of cardiovascular risk and CKD progression. Screen for it regularly in hypertensive patients.
• Treatment:
  • BP Control is Paramount: Aggressive and consistent BP control is the single most effective intervention to slow disease progression.
  • RAAS Inhibitors First-Line: ACEi/ARBs are renoprotective beyond just BP lowering. They are generally preferred for patients with hypertensive nephropathy, especially if proteinuria is present.
  • Don't Fear Creatinine Rise (within limits): A modest rise in serum creatinine (up to 30%) after initiating or increasing ACEi/ARB is expected and generally acceptable, reflecting reduced intraglomerular pressure. Monitor closely, but don't stop the drug prematurely.
  • SGLT2 Inhibitors: Recognize their growing role in cardiorenal protection in CKD, even in non-diabetics with proteinuria.
  • Holistic Approach: Emphasize lifestyle modifications as foundational to medication.
• Pitfalls:
  • Under-treatment of Hypertension: Many patients do not reach BP goals, leading to preventable progression.
  • Over-aggressive BP lowering: In acute settings (hypertensive emergency), can cause renal hypoperfusion.
  • Missing Secondary Hypertension: Failing to investigate for conditions like renal artery stenosis, primary aldosteronism, or pheochromocytoma, especially in resistant hypertension or early-onset/severe hypertension.
  • Ignoring Proteinuria: Not monitoring UACR or dismissing mild proteinuria as insignificant.
  • Polypharmacy and Interactions: Especially in older adults, careful medication reconciliation is necessary.

Recent Updates

• Guidelines:
  • KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease: Strongly recommends a systolic BP target of <120 mmHg (measured by standardized office BP) for most CKD patients, especially with albuminuria. This is lower than previous targets.
  • ACC/AHA 2017 Hypertension Guidelines: Defined hypertension as SBP ≥130 mmHg or DBP ≥80 mmHg, encouraging earlier and more aggressive intervention.
• Evidence:
  • SGLT2 Inhibitor Trials: Landmark trials (e.g., CREDENCE, DAPA-CKD, EMPA-KIDNEY) have demonstrated significant benefits of SGLT2 inhibitors in reducing the progression of CKD and cardiovascular events in patients with CKD, including those without diabetes. This has led to their strong recommendation in CKD management algorithms.
  • MRA Trials: Newer non-steroidal MRAs (e.g., Finerenone) show promise in reducing cardiorenal events with a lower risk of hyperkalemia compared to traditional MRAs, particularly in diabetic CKD patients.
• Controversies:
  • Optimal BP Target in CKD: While KDIGO 2021 recommends <120 mmHg SBP, the optimal target is still debated due to concerns about the generalizability of trial data, risk of adverse events (e.g., hypotension, AKI) with aggressive lowering in frail patients, and low certainty of evidence for some subgroups. Individualization remains key.
  • Role of Renal Denervation: While promising for resistant hypertension, its role in preventing or treating hypertensive nephropathy specifically requires more long-term data.
  • Genetic Testing: The role of APOL1 genetic testing in managing hypertensive nephropathy, particularly in African American patients, is evolving. While it identifies risk, clinical management decisions are not yet routinely based on it.

Key References

• Guidelines:
  • Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3S):S1-S87.
  • Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-e248.
  • KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.
• Studies:
  • CREDENCE Trial: Perkovic V, Jardine M, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306.
  • DAPA-CKD Trial: Heerspink HJL, Stefansson B, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446.
  • EMPA-KIDNEY Trial: The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Mar 2;388(10):117-128.
  • SPRINT Trial: The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26;373(22):2103-2116. (Influential for lower BP targets, though excluded those with baseline advanced CKD).
• Reviews:
  • Bakris GL. Recognition, pathogenesis, and treatment of hypertensive nephropathy. UpToDate (continuously updated review).
  • Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305.